Aspen HIV Prevention Pill Deal Expands African Access

Original Article by Tamar Kahn | Business Day | 27 July 2026

Aspen HIV prevention pill licensing deal positions the SA manufacturer to supply lower-cost monthly PrEP across key African markets.

Aspen HIV Prevention Pill Deal Expands African Access

Image | Gam1983 | iStock/1181839849

Aspen Pharmacare will become a major African supplier of Merck’s experimental monthly HIV prevention pill, alimatravir. The agreement depends on the medicine successfully completing clinical trials and receiving regulatory approval.

Merck granted voluntary licenses to seven generic drug manufacturers, including the South African company, to produce and distribute lower-cost versions of the medicine. The drug also goes by its development code, MK-8527.

Merck’s royalty-free agreements cover 129 low- and lower-middle-income countries. Licensed manufacturers will be able to supply patients in both the public and private healthcare sectors.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

Older Adults With HIV Set To Double By 2040

Older adults with HIV will nearly double by 2040. South Africa faces one of the sharpest rises, straining health systems.

Read more...

Rosebank Health Village Expands Growthpoint Portfolio

Rosebank Health Village, a R100 million Growthpoint and Epione development, brings specialists, diagnostics and day surgery together.

Read more...

Global HIV Funding Cuts Put AIDS Progress At Risk

Global HIV funding cuts pushed financing to a 20-year low in 2025, threatening prevention, research and the goal of ending AIDS by 2030.

Read more...